High efficacy of hypofractionated proton therapy with 4 fractions of 5  Gy as a boost to 50 Gy photon therapy for localized prostate cancer.

CONCLUSION: Dose escalation with hypofractionated proton boost was as effective as reported with high dose-rate brachytherapy boost, and the GU and GI toxicity profile was very similar. The proton boost was also appropriate for patients with larger prostate volume, higher T-stage, and high-risk disease encompassing elective regional node photon therapy. PMID: 31431382 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research

Related Links:

Authors: Chen P, Wang H, Li M, Yang L, Mou F, Singh B, He JY, Zhang W Abstract 6,12-Diphenyl-3,9-diazatetraasterane-1, 5, 7, 11-tetracarboxylate (DDTC) has been synthesized by the photodimerization of 4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate. The potential of theercvantitumor activity and mechanism were investigated in vitro using MTT assay in human lung cancer cell line A549, ovarian cancer cell lines SKOV3 and A2780, breast cancer cell line MCF-7, gastric cancer cell line BGC-823, colon cancer cell line HT29, prostate cancer cell line DU145, and liver cancer cell line SMMC7721. The results show that DDTC ca...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Authors: Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, Olmos D, Boccardo F, Zanardi E Abstract Despite chemotherapy and novel androgen-receptor signalling inhibitors (ARSi) have been approved during the last decades, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with poor clinical outcomes. Several studies found that germline or acquired DNA damage repair (DDR) defects affect a high percentage of mCRPC patients. Among DDR defects, BRCA mutations show relevant clinical implications. BRCA mutations are associated with adverse clinical features in primary tumors and...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Background: Androgen deprivation therapy (ADT) is extensively used in prostate cancer. Yet the risk of impaired cognition or Alzheimer disease (AD) in men with prostate cancer receiving ADT is uncertain. Some studies of prostate cancer and ADT suggest that the risk of AD is not increased. But other studies have found an increased risk of AD and cognitive impairment. Objectives: As the uncertainty about ADT and dementia might relate to the genetics of prostate cancer and AD, the authors used the Cancer Genome Atlas (TCGA) to examine the relationship in men with prostate cancer between genes implicated in AD and genes i...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
Radiopharmaceutical company Telix Pharmaceuticals has submitted a new drug...Read more on AuntMinnie.comRelated Reading: RefleXion, Telix partner on high-risk cancer treatments Companies partner on gallium-68 imaging ANMI inks deal for SPECT radiopharmaceutical
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Authors: Qian C, Liao CH, Tan BF, Chen YF, Dang BW, Chen JL, Liu CB Abstract Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, "LncRNA PROX1-AS1 promotes proliferation, invasion, and migration in prostate cancer via targeting miR-647, by C. Qian, C.-H. Liao, B.-F. Tan, Y.-F. Chen, B.-W. Dang, J.-L. Chen, C.-B. Liu, published in Eur Rev Med Pharmacol Sci 2020; 24 (6): 2938-2944-DOI: 10.26355/eurrev_202003_20658-PMID: 32271411" has been withdrawn. The Publisher apologizes for any inconvenience t...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
When used in combination with abiraterone, the new drug showed activity in metastatic castration-resistant prostate cancer in the IPATential 150 trial.Medscape Medical News
Source: Medscape Urology Headlines - Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news
Find out how the techniques and technology of the prostate biopsy have evolved in recent years -- and learn how these changes could impact the field of prostate cancer diagnosis.Translational Andrology and Urology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Urology Journal Article Source Type: news
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
In this study, feasibility was defined as the ability to distinguish between a positive and negative surgical margin, imaging within 45  min and low radiation exposure to staff.MethodsSix patients were included in this ongoing study. Following perioperative i.v. injection of ~  100 MBq68Ga-PSMA, the prostate was excised and immediately imaged ex vivo. Different acquisition protocols were tested, and hotspots on CLI images from the intact prostate were marked for comparison with histopathology.ResultsBy using an acquisition protocol with 150  s exposure time, 8 × 8 binning and a 550...
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Prostate cancer is a very common and highly fatal in men. Current non-invasive detection methods like serum biomarker are unsatisfactory. Biomarkers with high accuracy for diagnostic of prostate cancer are urg...
Source: BMC Medical Informatics and Decision Making - Category: Information Technology Authors: Tags: Research Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Gastroenterology | Prostate Cancer | Proton Therapy | Radiology | Toxicology